Beclomethasone 17-Monopropionate: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Beclomethasone 17-Monopropionate. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Pharyngitis | 27% |
| Headache | 25% |
| Increased asthma symptoms | 18% |
| Upper resp tract infection | 17% |
| Rhinitis | 15% |
| Oral symptoms inhalation route | 7% |
| Sinusitis | 7% |
| Dysphonia | 6% |
| Pain | 5% |
| Nausea | 5% |
| Back pain | 4% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids. Beclomethasone dipropionate is NOT indicated for the relief of acute bronchospasm.
Source: FDA labeling via NIH DailyMed (set a0e6af3a…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.